https://scholars.lib.ntu.edu.tw/handle/123456789/503634
標題: | Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan | 作者: | YU-TING CHANG MING-CHU CHANG KAI-WEN HUANG CHIEN-CHIH TUNG CHIUN HSU Wong J.-M. |
公開日期: | 2014 | 出版社: | Blackwell Publishing | 卷: | 29 | 期: | 5 | 起(迄)頁: | 1119-1125 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Background and Aim: Biliary tract carcinomas (BTCs) are difficult to diagnose and treat. Epidermal growth factor receptor (EGFR) represents a therapeutic target for the BTCs. Mutations of the EGFR gene and the activation of its downstream pathways, including KRAS and BRAF, predict the sensitivity to anti-EGFR treatment. The aims of this study were to analyze the EGFR, KRAS and BRAF mutations in BTCs and their association with clinical outcomes. Methods: Paraffin-embedded specimens containing 137 BTCs resected at the National Taiwan University Hospital between 1995 and 2004 were analyzed. The exons 18-21 of EGFR gene, the codon 12, 13 and 61 of KRAS gene, and BRAF V600E mutation were analyzed. We examined the correlation between these mutations and the overall survival, tumor location, stage, and differentiation in BTCs. Results: Thirteen (9.5%) BTC patients had EGFR mutations while 23 (16.8%) patients had KRAS mutations. Only one patient had BRAF mutation. Factors influencing survival on univariate analysis were tumor stage, tumor differentiation, and EGFR mutation. On multivariate analysis, EGFR mutation and tumor stage were independent prognostic factors. A correlation between KRAS or BRAF mutations and prognosis was not observed. Conclusions: EGFR and KRAS mutations are not uncommon in BTCs. BRAF mutation is rare in BTCs. EGFR mutation was an independent prognostic marker in BTCs in addition to tumor stage and differentiation. No simultaneous EGFR and KRAS mutations in extrahepatic cholangiocarcinoma and gallbladder carcinoma were found. EGFR and KRAS mutations should be evaluated when tailoring molecular-targeted therapy to patients with BTCs. ? 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898838514&doi=10.1111%2fjgh.12505&partnerID=40&md5=2c946361233e4fa8c06d1a8432b90dd3 https://scholars.lib.ntu.edu.tw/handle/123456789/503634 |
ISSN: | 0815-9319 | DOI: | 10.1111/jgh.12505 | SDG/關鍵字: | B Raf kinase; epidermal growth factor receptor; genomic DNA; K ras protein; B Raf kinase; BRAF protein, human; codon; EGFR protein, human; epidermal growth factor receptor; KRAS protein, human; oncoprotein; Ras protein; adult; aged; article; bile duct carcinoma; cancer patient; cancer prognosis; cancer survival; codon; disease association; exon; female; gallbladder carcinoma; gene mutation; high resolution melting analysis; human; human tissue; male; overall survival; priority journal; Taiwan; tumor differentiation; Biliary Tract Neoplasms; cancer staging; cell transformation; genetics; middle aged; molecularly targeted therapy; mutation; pathology; prognosis; very elderly; Adult; Aged; Aged, 80 and over; Biliary Tract Neoplasms; Cell Transformation, Neoplastic; Codon; Exons; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; ras Proteins; Receptor, Epidermal Growth Factor; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。